Nima Farzan Sells 2,625 Shares of Keros Therapeutics (NASDAQ:KROS) Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) Director Nima Farzan sold 2,625 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.73, for a total transaction of $28,166.25. Following the transaction, the director directly owned 9,767 shares of the company’s stock, valued at $104,799.91. This trade represents a 21.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Keros Therapeutics Stock Performance

Shares of KROS traded down $0.30 during midday trading on Monday, hitting $10.00. 169,361 shares of the company traded hands, compared to its average volume of 378,172. The firm has a 50 day moving average of $11.33 and a 200-day moving average of $15.15. Keros Therapeutics, Inc. has a 52 week low of $9.79 and a 52 week high of $22.55. The stock has a market cap of $197.92 million, a price-to-earnings ratio of -3.32 and a beta of 0.94.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Thursday, May 14th. The company reported ($1.21) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.19). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%. The company had revenue of $0.37 million for the quarter, compared to the consensus estimate of $1.93 million. Sell-side analysts predict that Keros Therapeutics, Inc. will post -5.19 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on KROS shares. Wells Fargo & Company decreased their target price on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, March 5th. Weiss Ratings cut shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 15th. Finally, Wall Street Zen cut shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Three research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $20.40.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KROS. ADAR1 Capital Management LLC lifted its holdings in Keros Therapeutics by 416.2% during the 1st quarter. ADAR1 Capital Management LLC now owns 97,318 shares of the company’s stock valued at $1,074,000 after buying an additional 78,467 shares in the last quarter. Empowered Funds LLC increased its position in shares of Keros Therapeutics by 142.2% during the first quarter. Empowered Funds LLC now owns 145,517 shares of the company’s stock worth $1,607,000 after acquiring an additional 85,439 shares during the period. Quantinno Capital Management LP increased its position in shares of Keros Therapeutics by 12.5% during the first quarter. Quantinno Capital Management LP now owns 23,759 shares of the company’s stock worth $262,000 after acquiring an additional 2,639 shares during the period. Lazard Asset Management LLC purchased a new position in shares of Keros Therapeutics during the first quarter worth approximately $129,000. Finally, Globeflex Capital L P purchased a new position in shares of Keros Therapeutics during the first quarter worth approximately $418,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.